Literature DB >> 2149296

Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites.

K Jhamandas1, R J Boegman, R J Beninger, M Bialik.   

Abstract

Certain products of tryptophan metabolism interact with excitatory amino acid receptors to produce or protect against excitotoxicity. In this study, the action of several tryptophan metabolites, yielded by the kynurenine pathway, on cortical cholinergic toxicity was evaluated following focal injection into the rat nucleus basalis magnocellularis (nbM). Metabolites were injected singly or in combination with a fixed dose of quinolinic acid (QUIN). Cholinergic toxicity, or protection against it, was evaluated by measurements of choline acetyltransferase (ChAT) activity or potassium-evoked release of [3H]acetylcholine [( 3H]ACh) from slices of the frontoparietal cortex, from the injected and uninjected sides. Focal injections of QUIN and 3-hydroxyanthranilic, but not kynurenic, picolinic, quinaldic or anthranilic acid, produced a dose-related decrease in ChAT activity, with QUIN being more potent. Kynurenic, picolinic, quinaldic and anthranilic acid, co-injected into the nbM with QUIN (120 nmol), produced dose-related antagonism of the neurotoxicity associated with QUIN alone. Picolinic acid also prevented the reduction in cortical [3H]ACh release induced by injections of QUIN. Kynurenic and picolinic acid produced a complete blockade of QUIN's effect on cortical ChAT activity, while quinaldic and anthranilic acid produced a partial blockade. The order of effectiveness against QUIN was kynurenic greater than picolinic greater than quinalidic or anthranilic acid. Evaluation of thin sections following Cresyl violet staining indicated that injections of QUIN produced neuronal loss and glial proliferation, while co-injections of picolinic or quinaldic acid with QUIN protected neurons. These findings show that several tryptophan metabolites have the potential to either produce or antagonize cholinergic toxicity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149296     DOI: 10.1016/0006-8993(90)90826-w

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  30 in total

1.  Maternal Inflammation Results in Altered Tryptophan Metabolism in Rabbit Placenta and Fetal Brain.

Authors:  Monica Williams; Zhi Zhang; Elizabeth Nance; Julia L Drewes; Wojciech G Lesniak; Sarabdeep Singh; Diane C Chugani; Kannan Rangaramanujam; David R Graham; Sujatha Kannan
Journal:  Dev Neurosci       Date:  2017-05-11       Impact factor: 2.984

Review 2.  Where does a migraine attack originate? In the brainstem.

Authors:  J Tajti; D Szok; Á Párdutz; B Tuka; A Csáti; A Kuris; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

3.  Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition.

Authors:  Catherine J Clark; Gillian M Mackay; George A Smythe; Sonia Bustamante; Trevor W Stone; R Stephen Phillips
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

Review 4.  Kynurenines and headache.

Authors:  Arpád Párdutz; Annamária Fejes; Zsuzsanna Bohár; Lilla Tar; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-06-04       Impact factor: 3.575

5.  Excitotoxicity of quinolinic acid: modulation by endogenous antagonists.

Authors:  K H Jhamandas; R J Boegman; R J Beninger; A F Miranda; K A Lipic
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

6.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

7.  Biochemical identification and crystal structure of kynurenine formamidase from Drosophila melanogaster.

Authors:  Qian Han; Howard Robinson; Jianyong Li
Journal:  Biochem J       Date:  2012-09-01       Impact factor: 3.857

Review 8.  The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce Brew; Gilles Guillemin
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

Review 9.  Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.

Authors:  D Zádori; P Klivényi; E Vámos; F Fülöp; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2009-07-18       Impact factor: 3.575

10.  The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.

Authors:  Yiquan Chen; Roger Stankovic; Karen M Cullen; Vincent Meininger; Brett Garner; Sarah Coggan; Ross Grant; Bruce J Brew; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2009-11-18       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.